▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #897 by analyst upside · 2026-11-13
OVID
Ovid Therapeutics Inc.
Healthcare · Market Cap $481M · P/E 0x
ANALYST PRICE TARGET
+141.2%
implied upside to consensus target
Current Price $2.55
Consensus Target $6.15
Bull Target $9.0
Bear Target $4.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
10
Hold
0
Sell
0
52-Week Low $1.18
52-Week High $3.1
YTD Return +44.9%
FUNDAMENTALS
Market Cap $481M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.18
52-Week High $3.1
Current Price $2.55
Bear Target $4.0
Bull Target $9.0
● Now $2.55 ● Target $6.15
TRADING DATA
Avg Volume 1.9M
YTD Return +44.9%
Analyst Count 10
Consensus Buy
Upside to Target +141.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Ovid Therapeutics Inc. (OVID) is currently trading at $2.55 with a Wall Street consensus price target of $6.15, implying potential upside of 141.2% over the next 12 months. 10 analysts currently cover OVID, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $4.0.

OVID operates in the Healthcare sector with a market capitalisation of $481M. The stock is up 44.9% year-to-date and is currently trading near the upper end of its 52-week range of $1.18 – $3.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for OVID, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wolfe Research ● Initiated
Outperform 2026-10-15 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-10-09 40% win rate (10 calls)
Guggenheim ● Initiated
Buy 2026-10-06 62% win rate (8 calls)
Guggenheim ● Initiated
Buy 2026-10-05 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-11 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-08-03 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-04-15 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-04-09 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →